David Epstein - Articles and news items


Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials

Industry news / 8 July 2014 / Novartis

Novartis released new global guidelines for Investigator Initiated Trials…


Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista®

Industry news / 20 May 2014 / Novartis

Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States…


Novartis introduces Lucentis® in state of the art pre-filled syringe

Industry news / 20 March 2014 / Novartis

Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014…


Novartis announces Xolair® approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines

Industry news / 6 March 2014 / Novartis

Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients…

Novartis logo

Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU

Industry news / 24 January 2014 / Novartis

Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure…

Novartis logo

Real-world evidence showed superiority of Novartis’ Gilenya® to reduce MS relapse rates compared to interferons or glatiramer acetate

Industry news / 3 October 2013 / Novartis

“Controlling relapses and preventing disability are key treatment goals for patients with MS…”

Novartis logo

Novartis to reveal landmark Phase III results from specialty dermatology portfolio at upcoming EADV 2013 congress

Industry news / 1 October 2013 / Novartis

Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed…

Novartis logo

Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]

Industry news, News / 2 September 2013 / Novartis

New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]…

Novartis logo

Novartis first in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD

Industry news, News / 26 July 2013 / Novartis

Novartis announced that the EMA’s CHMP has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®…

Novartis logo

FDA grants breakthrough therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure

Industry news, News / 21 June 2013 / Novartis

RLX030 has the potential to address a serious unmet medical need…

Novartis logo

World MS Day: Novartis launches a new campaign to raise awareness of MS

Industry news, News / 29 May 2013 / Novartis

Novartis is joining the global multiple sclerosis community in celebration of World MS Day…

Novartis logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...